AZD2624 Multiple Ascending Dose Study in Japan

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-05-31

Study Completion Date

2008-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This multiple ascending dose study will evaluate safety and tolerability after repeated ascending doses of AZD2624

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Multiple Ascending Dose Study for AZD 7268 in Japanese Healthy Male Volunteers

NCT01116011

Healthy

COMPLETED PHASE1

Study to Assess the Safety, Tolerability and Pharmacokinetics After Multiple Doses of AZD2066 in Japanese Subjects

NCT00766012

Healthy

COMPLETED PHASE1

Single and Multiple Ascending Doses of AZD1981 in Japan

NCT00698282

Healthy

COMPLETED PHASE1

AZD8529 Single Ascending Dose Study in Healthy Japanese Subjects

NCT00886756

Healthy

COMPLETED PHASE1

AZD7325 Single Ascending Dose Study in Healthy Male Japanese Subjects

NCT00769899

Healthy Volunteer

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Safety

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type EXPERIMENTAL

AZD2624

Intervention Type DRUG

oral suspension, 3 doses

2

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AZD2624

oral suspension, 3 doses

Intervention Type DRUG

Placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy young male Japanese volunteers

Exclusion Criteria

* Significant illness, as judged by the investigator, within 2 weeks of screening visit or Day 1
* Enrollment in another concurrent investigational study or intake of an investigational drug within 4 months prior to the screening visit or Day 1
* Blood loss in excess of 200 mL within 30 days of screening visit or Day 1, in excess of 400 mL within 90 days of screening visit or Day 1, or in excess of 1200 mL within 1 year of screening visit or Day 1
* Clinically relevant abnormalities in physical examinations, vital signs, clinical chemistry, hematology or urinalysis as judged by the investigator at screening or pre first dose

Minimum Eligible Age

20 Years

Maximum Eligible Age

45 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes